Mouse / Rat C-Peptide ELISA Kit

C-Peptide

-20°C

Plasma, Serum

Colorimetric

96-well Microplate

Pre-Coated 96-well Strip Microplate
Wash Buffer
Standard Peptide
Assay Diluent(s)
Biotinylated Peptide
HRP-Streptavidin
TMB One-Step Substrate
Stop Solution
Assay Diagram
Positive Control Sample
Capture Antibody
User Manual

Prepare all reagents, samples and standards as instructed.
Add 100 µl detection antibody to each well.
Incubate 1.5 h at RT or O/N at 4°C.
Add 100 µl standard or sample to each well.
Incubate 2.5 h at RT.
Add 100 µl prepared streptavidin solution.
Incubate 45 min at RT.
Add 100 µl TMB One-Step Substrate Reagent to each well.
Incubate 30 min at RT.
Add 50 µl Stop Solution to each well.
Read plate at 450 nm immediately.

41116158

This EIA kit is designed to detect mouse, and rat C-Peptide.

C-Peptide is a 31-amino acid single-chain peptide that is made when proinsulin is split into insulin and C-Peptide. They split before proinsulin is released from endocytic vesicles within the pancreas-one C-Peptide for each insulin molecule. C-Peptide is the middle segment of proinsulin that is between the N-terminal B-chain (30 amino acids) and the C-terminal A-chain (21 amino acids). Unlike insulin, C-Peptide has no known physiological function. Due to the fact that C-Peptide has a 2-to-5-time longer half-life than insulin, there are higher concentrations of C-Peptide than insulin in the peripheral circulation. Therefore, plasma C-Peptide concentrations may reflect pancreatic insulin secretion more reliably than the level of insulin itself. C-Peptide is cleared from the body by the kidney, and, unlike insulin, urine concentrations are 20 - 50 times higher than in plasma. Unlike plasma insulin levels, which fluctuate in response to meals, measurement of the 24-hour urinary excretion of C-Peptide provides a useful monitor of average beta cell insulin secretion.The level of C-Peptide has been used to assess the following clinical applications
to assess the residual beta cell function in patients treated with insulin and to distinguish between types 1 and 2 diabetes. Of particular interest is its use to indicate the need for progression to insulin therapy in type 2 diabetes.
The diagnosis of factitious hypoglycemia. The surreptitious administration of insulin causes high insulin levels in the absence of elevated C-Peptide concentrations.
Insulinoma diagnosis, especially in patients treated with insulin. C-Peptide measurement is used in insulin suppression tests in euglycemic patients with suspected insulinoma. Elevated C-Peptide levels in this test are indicative of insulinoma.
As a marker for residual pancreatic tissue after pancreatectomy. In the case of insulinoma, C-Peptide measurement may be used to detect metastasis and the response to therapy. It may also be used to monitor the progress of pancreas or islet cell transplantation